Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

Drug Substance Development

Talented people, smart processes and cutting-edge equipment – we have the perfect formula to meet all your process development and scale-up needs.

Page
Read more

Membrane Technology

Hovione has a wide range of membrane capabilities at its disposal including nanofiltration and ultrafiltration.

Page
Read more

Certificate of Suitability (CEP)

EP Certificates - Granted by EDQM

Page
Read more